Apellis Pharmaceuticals, which is developing a novel protein inhibitor for autoimmune and inflammatory diseases, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
The Crestwood, KY-based company, which was founded in 2009, plans to list on the Nasdaq under the symbol APLS. Apellis Pharmaceuticals initially filed confidentially on August 19, 2015. Citi, Barclays and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
